PALO ALTO, Calif., April 10, 2024 BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the.
Moody Aldrich Partners LLC decreased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 124,984 shares of the company’s stock after selling 12,528 shares during the period. Moody Aldrich Partners LLC owned about 0.07% […]
Moody Aldrich Partners LLC cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 124,984 shares of the company’s stock after selling 12,528 shares during the period. Moody Aldrich Partners LLC’s holdings in BridgeBio Pharma were worth $5,046,000 as of […]
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
China Universal Asset Management Co Ltd Acquires 15,949 Shares of BridgeBio Pharma, Inc (NASDAQ:BBIO) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.